CE Mark Brings Baxter’s VIVIA High Dose Hemodialysis System to Europe

Baxter International Inc. has gained CE mark approval for its VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy.


An estimated 1.9 million end-stage kidney disease (ESKD) patients worldwide undergo hemodialysis, with the vast majority receiving conventional hemodialysis (CHD), which is usually performed three times a week for three to five hours per session in a center or clinic.

High Dose HD therapy is a more frequent therapy usually performed as short daily treatments at least five days per week for sessions that typically run less than four hours, or as nocturnal treatments where sessions are conducted for greater than six hours while the patient sleeps. High Dose HD therapy is associated with improvements in survival and clinically important health measures, including health-related quality of life, compared with CHD.

Baxter’s VIVIA is designed with the patient as the primary operator. Its touch screen and graphic user interface displays large, easy-to-comprehend graphics and animations that help guide patients through setup, treatment and cleanup. VIVIA’s Access Disconnect Sensor causes the system to stop pumping if the needle dislodges. The system also has one-button fluid infusion to help minimize user error and promote additional safety for the patient.

To support the important interface between patients and their healthcare practitioners, VIVIA includes the fully integrated Sharesource wireless connectivity platform that allows physicians and nurses to comprehensively monitor home therapy remotely.

Following its new approval, Baxter says it will introduce VIVIA in a limited number of European dialysis clinics in 2014 to allow patients and healthcare providers to become familiar with the system and its patient-friendly features. Baxter plans to expand the launch to other European countries in 2015.

Company comments

”At Baxter, we are committed to providing physicians and their patients with product and therapy options for the best clinical outcomes possible,” said Brik Eyre, president of Baxter’s Renal business. ”The VIVIA system was developed to support renal patients’ unmet need for an innovative home-based hemodialysis option.”

”Globally, less than 1 percent of the estimated 1.9 million patients requiring hemodialysis currently perform High Dose HD therapy,” said Bruce Culleton, M.D., senior medical director, Baxter. ”VIVIA will allow a greater number of hemodialysis patients access to High Dose HD therapy in their home environment.”

Source: Baxter International, Inc., Business Wire

Share your thoughts

Your email address will not be published. Required fields are marked *